{"id":978081,"date":"2026-07-02T04:05:55","date_gmt":"2026-07-02T08:05:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\/"},"modified":"2026-07-02T04:05:55","modified_gmt":"2026-07-02T08:05:55","slug":"oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\/","title":{"rendered":"Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">ZUG, Switzerland, July  02, 2026  (GLOBE NEWSWIRE) &#8212; Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (\u201cOculis\u201d or the \u201cCompany\u201d), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs, announced today that Oculis\u2019 management will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Conference.<\/p>\n<p align=\"justify\">The Company will provide an overview and update of its innovative current late-stage portfolio. Key highlights include: <strong>Privosegtor<\/strong>, a novel neuroprotective candidate which received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for optic neuritis (ON), in the <strong>PIONEER <\/strong>registrational program to address unmet needs for two optic neuropathies targeting an estimated potential market opportunity of $7B+ in the U.S. alone, and <strong>Licaminlimab<\/strong>, a topical anti-TNF\u03b1 being evaluated in the <strong>PREDICT-1<\/strong> registrational trial as the first genotype-based precision medicine approach in dry eye disease (DED).<\/p>\n<p align=\"justify\">With a strong balance sheet and advanced pipeline, Oculis is well positioned to deliver value-driving milestones across our targeted registrational programs, focusing on fulfilling its mission to save sight and improve eye care with groundbreaking treatments.<\/p>\n<p>\n        <strong>Piper Sandler Virtual Ophthalmology Conference<\/strong><br \/>\n        <br \/>Date: July 10, 9:30am ET<br \/>Location: Miami, FL<br \/>Format: Fireside chat<br \/>Presenter: Sylvia Cheung, CFO<\/p>\n<p>The Company will be available for one-on-one meetings during the conference. Interested investors should contact their Piper Sandler &amp; Co. (PSC) sales representative for registration information or to request a meeting.<\/p>\n<p>\n        <strong>About Oculis<\/strong>\n      <\/p>\n<p align=\"justify\">Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology. Oculis\u2019 highly differentiated late-stage clinical pipeline focuses on two core product candidates. Privosegtor is a breakthrough neuroprotective candidate in the PIONEER program, which consists of studies intended to support registration plans for treatment of optic neuropathies, including optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION). Privosegtor also has potential to be developed for additional indications in other neuro-ophthalmic and neurological diseases. Licaminlimab is a novel, topical anti-TNF\u03b1 in a registrational trial, and is being developed with a genotype-based approach for treating patients with dry eye disease (DED). Headquartered in Switzerland with operations in the U.S., Iceland and Switzerland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.<\/p>\n<p>For more information, please visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HOVaRC_w6RZ5lQga6I4hzHp3-qcl91RYDok9OtHLTVwNJhUcb30vCovxp4-B_bpgo1X6vI6_usfoaHc3oCRQEA==\" rel=\"nofollow\" target=\"_blank\">www.oculis.com<\/a><\/p>\n<p>\n        <strong>Oculis Contacts<\/strong><br \/>\n        <br \/>Sylvia Cheung, CFO<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=V5WbZvAKnecXPojEgcG3cM-NNHYJWyjm6RljdZDvrPaCSoLtKiJnDa3qHilfdNpfEYhyaEQ151-MCpd7V85VbXesubTCSWICFB8Rbs-0nCjDm2vIQRk9pAHZineKY6JPZnaJqRXrYFOR9a74R1pUN0Orkb5bqsbtrkDq6vrAsyO4QSMXO-wd_QoZrLIHeSZyKqX4Tl_1ShZH1Zc3zFwiMVDoMhuQXfd8YhKQJDBdXX9UTPLiY8KgslARZa6wjZjiJZfsmfUq_Sr7ODY4nzwWvH_naG78PdPGeol89N9FkXw=\" rel=\"nofollow\" target=\"_blank\"><u>sylvia.cheung@oculis.com<\/u><\/a><\/p>\n<p>\n        <strong>Investor Relations <\/strong><br \/>\n        <br \/>LifeSci Advisors<br \/>Corey Davis, Ph.D.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NYCh7VI6mRxgRo45_yrGq-DCyLk9GWMk9IoJipLjFSI2vnChPAlzTLxGnKWXA0p_YLthk43_buQruMKfKvLbCJdiYvlfuTVih6_JpD-rVH_JCdmQX1uIDf282klv4n3g\" rel=\"nofollow\" target=\"_blank\">cdavis@lifesciadvisors.com<\/a><\/p>\n<p>\n        <strong>Media Relations<\/strong><br \/>\n        <br \/>ICR Healthcare<br \/>Amber Fennell \/ David Daley \/ Sean Leous<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=d7ZvUmZfRxBFMJ_jgQ5xd2jU3cVE6aPj7VWT971gQeZBMBJXNmi6-IkT8AyPNKAIV9Pmx2djdpdF7amh74OUwxM66YRerUiaNpxkXpSxrBHTbGC4RpwhjFWhquFpsFqpJEepbH-JK7doOvL41QsMD7-Ozfrvj1Ly3jXfsffyA8LXb0av3T67KdOkuSnos1Gjpw7l5CPRs2x6dYG1p4BCxLsENOolrdpTI66E5zuyo_moBIi7FgzcacHG5AJHRCmgNO7uH4GqYTWNj2V9DfgDxeAAqhjfUFlQDq1Tl6CG4KtEKcBSSQZIljrulmuwavnzHHDcAmq4M6XTjIOUTzXMKvucIb1XsUWQbF5sHx2-GE9xAcAsSlr156Dj0gdpGZVZ8D7GPlatVye8Oxf__44WHxRz615Qdmi5qu0W6JdzC1X-j5KZ-6y-vklutgfwhkNIJ9sV6nE0RVJbWv1Av1_b-mDhVPs0gmD-Oo-6M7ynFq6HVWxuLkITDTJsQXaLLHXGxg__BHCMCVgscKXGVDwH1KBa3b_vs149s4x0jR_HOmgDj6tPl2tv1oNtyamtKbsR\" rel=\"nofollow\" target=\"_blank\">oculis@icrhealthcare.com<\/a><\/p>\n<p>\n        <strong>Cautionary Statement Regarding Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company\u2019s product candidates, including the initiation, timing, progress and results of current and future clinical trials, Oculis\u2019 research and development programs, regulatory and business strategy; expected milestones and ability to deliver value-driving milestones; statements about market opportunity; and statements about cash runway and capital needs, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis\u2019 control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and\/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis\u2019 annual report on Form 20-F and any other documents filed with the SEC. Copies of these documents are available on the SEC\u2019s website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTIxMDcyNCM0MDI0Mzc1OTYjMjE4OTAyMw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/ZDljMzFiMGEtZGMwYi00OGFlLTg5YWEtZGU3Zjc4YWNiMTZmLTEyMDA1NzYtMjAyNi0wNy0wMi1lbg==\/tiny\/Oculis-Holding-AG.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ZUG, Switzerland, July 02, 2026 (GLOBE NEWSWIRE) &#8212; Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (\u201cOculis\u201d or the \u201cCompany\u201d), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs, announced today that Oculis\u2019 management will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Conference. The Company will provide an overview and update of its innovative current late-stage portfolio. Key highlights include: Privosegtor, a novel neuroprotective candidate which received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for optic neuritis (ON), in the PIONEER registrational program to address unmet needs for two optic neuropathies targeting an estimated &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-978081","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ZUG, Switzerland, July 02, 2026 (GLOBE NEWSWIRE) &#8212; Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (\u201cOculis\u201d or the \u201cCompany\u201d), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs, announced today that Oculis\u2019 management will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Conference. The Company will provide an overview and update of its innovative current late-stage portfolio. Key highlights include: Privosegtor, a novel neuroprotective candidate which received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for optic neuritis (ON), in the PIONEER registrational program to address unmet needs for two optic neuropathies targeting an estimated &hellip; Continue reading &quot;Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-02T08:05:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTIxMDcyNCM0MDI0Mzc1OTYjMjE4OTAyMw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference\",\"datePublished\":\"2026-07-02T08:05:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\\\/\"},\"wordCount\":703,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTIxMDcyNCM0MDI0Mzc1OTYjMjE4OTAyMw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\\\/\",\"name\":\"Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTIxMDcyNCM0MDI0Mzc1OTYjMjE4OTAyMw==\",\"datePublished\":\"2026-07-02T08:05:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTIxMDcyNCM0MDI0Mzc1OTYjMjE4OTAyMw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTIxMDcyNCM0MDI0Mzc1OTYjMjE4OTAyMw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\/","og_locale":"en_US","og_type":"article","og_title":"Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference - Market Newsdesk","og_description":"ZUG, Switzerland, July 02, 2026 (GLOBE NEWSWIRE) &#8212; Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (\u201cOculis\u201d or the \u201cCompany\u201d), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs, announced today that Oculis\u2019 management will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Conference. The Company will provide an overview and update of its innovative current late-stage portfolio. Key highlights include: Privosegtor, a novel neuroprotective candidate which received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for optic neuritis (ON), in the PIONEER registrational program to address unmet needs for two optic neuropathies targeting an estimated &hellip; Continue reading \"Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-02T08:05:55+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTIxMDcyNCM0MDI0Mzc1OTYjMjE4OTAyMw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference","datePublished":"2026-07-02T08:05:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\/"},"wordCount":703,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTIxMDcyNCM0MDI0Mzc1OTYjMjE4OTAyMw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\/","name":"Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTIxMDcyNCM0MDI0Mzc1OTYjMjE4OTAyMw==","datePublished":"2026-07-02T08:05:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTIxMDcyNCM0MDI0Mzc1OTYjMjE4OTAyMw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTIxMDcyNCM0MDI0Mzc1OTYjMjE4OTAyMw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/978081","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=978081"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/978081\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=978081"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=978081"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=978081"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}